Clinical trials: Neoantigen
Melanoma
ATL001 in Patients With Metastatic or Recurrent Melanoma
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with…
- Trial name
- NCT03997474
- Testing
- ATL001, Checkpoint Inhibitor
- Where
- 10 sites in Spain, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Achilles Therapeutics UK Limited
Non-small Cell Lung Cancer, Neoantigen
Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
This multicenter prospective observational and exploratory study aims to develop and validate a novel multi-omics-based computational method for neoantigen prediction in non-small cell lung cancer (NSCLC), and discover biomarkers…
- Conditions
- Non-small Cell Lung Cancer, Neoantigen, Next-generation Sequencing, Biomarker
- Trial name
- MOTIVATION (NCT04923802)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- GeneCast Biotechnology Co., Ltd.
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab
This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with…
- Conditions
- Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- PANDA-VAC (NCT04266730)
- Testing
- PANDA-VAC, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer Metastatic, Colorectal Cancer Stage III
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
This is an early phase I, single-arm, open-label clinical study designed to evaluate the safety, tolerability, and feasibility of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen peptide…
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV
- Trial name
- COLONYVAQ™-CRC (NCT07328087)
- Testing
- Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
The main objective of this study is to observe and evaluate the safety and tolerability of the XP-005 personalized tumor mRNA vaccine, either alone or in combination with toripalimab, for the treatment of acute myeloid leukemia…
- Trial name
- NCT06980155
- Testing
- Personalized neoantigen tumor vaccine, PD-1 inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cutaneous Melanoma
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
This research study is investigating a new type of personalized neoantigen vaccine, NeoVax, plus Montanide® in combination with Ipilimumab (Yervoy™) and Nivolumab (Opdivo®) as a possible treatment for cutaneous melanoma.
- Trial name
- NCT03929029
- Testing
- Nivolumab (480 mg infusion), NeoVax plus Montanide, Ipilimumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Pancreas Cancer, Pancreatic Cancer
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
This is a randomized phase 1 clinical trial to evaluate the safety of an optimized neoantigen synthetic long peptide (SLP) vaccines in pancreatic cancer patients following neoadjuvant chemotherapy.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT05111353
- Testing
- Optimized neoantigen synthetic long peptide vaccine, Poly-ICLC
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
Advanced NSCLC
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-loaded dendritic cell (DC) vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT06752057
- Testing
- Radiotherapy, PD-1 inhibitor, Neoantigen-loaded DC vaccine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Urothelial/Bladder Cancer, Nos
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor…
- Trial name
- NCT03359239
- Testing
- Atezolizumab, PGV001, Poly ICLC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew Galsky
Endometrial Carcinoma, Endometrial Carcinoma Stage III
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma.
- Trial name
- GYNORYLAQ™ (NCT07316361)
- Testing
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Metastatic Melanoma
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma.
- Trial name
- NCT03597282
- Testing
- NEO-PV-01, Nivolumab, Adjuvant
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- BioNTech US Inc.
Solid Tumor
Prospective Tissue Collection Research Protocol
This is a multi-solid tumour research study which collects tumour samples from patients alongside a matched whole blood, and/or leukapheresis product for the development of manufacturing processes for potential immunotherapies.
- Trial name
- NCT03517917
- Testing
- Tumour tissue collection
- Where
- 18 sites in United States, Spain and 1 more
- Volunteers
- 221 people
- Sponsor
- AstraZeneca
Solid Cancer
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
The primary objective of this study is to evaluate the safety of TSA-CTL in the treatment of advanced solid tumors. The secondary objective of this study is to evaluate preliminarily the effect of TSA-CTL in the treatment of…
- Trial name
- NCT02959905
- Testing
- TSA-CTL, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 11 people
- Sponsor
- BGI, China
Pancreatic Cancer, Pancreas Cancer
Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
This is a phase 1 open-label study to evaluate the safety and immunogenicity of a neoantigen DNA vaccine strategy in pancreatic cancer patients following surgical resection and adjuvant chemotherapy.
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
- Trial name
- NCT03122106
- Testing
- Personalized neoantigen DNA vaccine, TDS-IM Electrode Array System, Peripheral blood draws
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04267237
- Testing
- Atezolizumab, RO7198457
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of…
- Trial name
- NCT05916248
- Testing
- Personalized neoantigen tumor vaccine, PD-1 inhibitor
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC
- Trial name
- NCT06913218
- Testing
- AK154, Cadonilimab, Ivonescimab (SMT112 or AK112) Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso